Educational information, not medical advice — ask your doctor or midwife.
Adenosylcobalamin is one of two active coenzyme forms of vitamin B12 (the other being methylcobalamin). Unlike the synthetic cyanocobalamin found in most cheap supplements, adenosylcobalamin is already in the form your mitochondria — the energy-producing centers of your cells — can use immediately. It's especially important for the health of your nervous system and for helping your body produce energy efficiently.
Adenosylcobalamin works inside the mitochondria as a cofactor for an enzyme called methylmalonyl-CoA mutase, which helps convert certain fats and proteins into usable fuel. This process is essential for maintaining healthy nerve cells and keeping energy metabolism running smoothly. Without enough adenosylcobalamin, a compound called methylmalonic acid builds up in the body — a reliable marker that your nerves and mitochondria aren't getting the B12 they need.
Adenosylcobalamin is most commonly found as sublingual tablets or lozenges, which bypass the gut's complex absorption process that requires a protein called intrinsic factor. Capsules are also available. Injectable forms exist in clinical settings. Because it is light-sensitive, quality products are typically packaged in dark or opaque containers.
Adenosylcobalamin was first isolated and characterized in the 1950s–1960s during landmark research into the chemistry of vitamin B12 coenzymes. It was recognized as the mitochondria-specific active form of B12 and has been studied extensively in the context of metabolic disease, nerve damage, and B12 deficiency disorders. Clinical interest grew as researchers noted that some patients with neurological B12 symptoms responded better to active coenzyme forms than to synthetic cyanocobalamin.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
Reviewed by the HealisticMD editorial team How we grade evidence →
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.